<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39186606</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2573-7732</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>ImmunoHorizons</Title><ISOAbbreviation>Immunohorizons</ISOAbbreviation></Journal><ArticleTitle>Mild Primary or Breakthrough SARS-CoV-2 Infection Promotes Autoantibody Production in Individuals with and without Neuro-PASC.</ArticleTitle><Pagination><StartPage>577</StartPage><EndPage>585</EndPage><MedlinePgn>577-585</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4049/immunohorizons.2400033</ELocationID><Abstract><AbstractText>Patients with long COVID can develop humoral autoimmunity after severe acute SARS-CoV-2 infection. However, whether similar increases in autoantibody responses occur after mild infection and whether vaccination prior to SARS-CoV-2 breakthrough infection can limit autoantibody responses is unknown. In this study, we demonstrate that mild SARS-CoV-2 infection increases autoantibodies associated with rheumatic autoimmune diseases and diabetes in most individuals, regardless of vaccination status prior to infection. However, patients with long COVID and persistent neurologic and fatigue symptoms (neuro-PASC) have substantially higher autoantibody responses than convalescent control subjects at an average of 8 mo postinfection. Furthermore, high titers of systemic lupus erythematosus- and CNS-associated autoantibodies in patients with neuro-PASC are associated with impaired cognitive performance and greater symptom severity. In summary, we found that mild SARS-CoV-2 primary and breakthrough infections can induce persistent humoral autoimmunity in both patients with neuro-PASC and healthy COVID convalescents, suggesting that a reappraisal of mitigation strategies against SARS-CoV-2 is warranted to prevent transmission and potential development of autoimmunity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Visvabharathy</LastName><ForeName>Lavanya</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8157-4385</Identifier><AffiliationInfo><Affiliation>Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalil</LastName><ForeName>Neda</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5566-4347</Identifier><AffiliationInfo><Affiliation>Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leonor</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Chengsong</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8872-9450</Identifier><AffiliationInfo><Affiliation>Genomics and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orban</LastName><ForeName>Zachary S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Millenia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Patrick H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penaloza-MacMaster</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9986-4906</Identifier><AffiliationInfo><Affiliation>Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koralnik</LastName><ForeName>Igor J</ForeName><Initials>IJ</Initials><Identifier Source="ORCID">0000-0001-6836-1468</Identifier><AffiliationInfo><Affiliation>Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 DA051912</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 EB027049</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Immunohorizons</MedlineTA><NlmUniqueID>101708159</NlmUniqueID><ISSNLinking>2573-7732</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000718127">COVID-19 breakthrough infections</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093742" MajorTopicYN="N">Breakthrough Infections</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no financial conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>19</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>14</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39186606</ArticleId><ArticleId IdType="pmc">PMC11374748</ArticleId><ArticleId IdType="doi">10.4049/immunohorizons.2400033</ArticleId><ArticleId IdType="pii">267113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Center for Health Statistics . 2023. Long COVID: household pulse survey. National Center for Health Statistics, Hyattsville, MD.</Citation></Reference><Reference><Citation>Thaweethai, T., Jolley S. E., Karlson E. W., Levitan E. B., Levy B., McComsey G. A., McCorkell L., Nadkarni G. N., Parthasarathy S., Singh U., et al. and RECOVER Consortium. 2023. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 329: 1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe, B., Xie Y., Al-Aly Z.. 2022. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat. Med. 28: 2398&#x2013;2405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, E. Y., Mao T., Klein J., Dai Y., Huck J. D., Jaycox J. R., Liu F., Zhou T., Israelow B., Wong P., et al. Yale IMPACT Team . 2021. Diverse functional autoantibodies in patients with COVID-19. Nature 595: 283&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, Y., Yuan D., Chen D. G., Ng R. H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. ISB-Swedish COVID-19 Biobanking Unit . 2022. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185: 881&#x2013;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Giraldo, G. S., Ali S. T., Kang A. K., Patel T. R., Budhiraja S., Gaelen J. I., Lank G. K., Clark J. R., Mukherjee S., Singer T., et al. . 2023. Neurologic manifestations of long COVID differ based on acute COVID-19 severity. Ann. Neurol. 94: 146&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10724021</ArticleId><ArticleId IdType="pubmed">36966460</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly, Z., Bowe B., Xie Y.. 2022. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28: 1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacio, N., Dangi T., Chung Y. R., Wang Y., Loredo-Varela J. L., Zhang Z., Penaloza-MacMaster P.. 2020. Early type I IFN blockade improves the efficacy of viral vaccines. J. Exp. Med. 217: e20191220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953731</ArticleId><ArticleId IdType="pubmed">32820330</ArticleId></ArticleIdList></Reference><Reference><Citation>Avalos, A., Tietsort J. T., Suwankitwat N., Woods J. D., Jackson S. W., Christodoulou A., Morrill C., Liggitt H. D., Zhu C., Li Q. Z., et al. . 2022. Hem-1 regulates protective humoral immunity and limits autoantibody production in a B cell-specific manner. JCI. Insight. 7: e153597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9090261</ArticleId><ArticleId IdType="pubmed">35531955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffatti, A., Rossi L., Calligaro A., Del Ross T., Lagni M., Marson P., Todesco S.. 1990. Autoantibodies of systemic rheumatic diseases in the healthy elderly. Gerontology 36: 104&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">2376330</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowley, M. J., Buchanan H., Mackay I. R.. 1968. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet 2: 24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">4172688</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy, L., Hanson B. A., Orban Z. S., Lim P. H., Palacio N. M., Jimenez M., Clark J. R., Graham E. L., Liotta E. M., Tachas G., et al. . 2023. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 nucleocapsid protein. Front. Immunol. 14: 1155770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10258318</ArticleId><ArticleId IdType="pubmed">37313412</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky, A., Wang C. Y., Saxena A., Mitchell A., Kung A. F., Takahashi S., Anglin K., Huang B., Hoh R., Lu S., et al. . 2023. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and long COVID patients. JCI Insight 8: e169515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10393220</ArticleId><ArticleId IdType="pubmed">37288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias Junior, A. G., Sampaio N. G., Rehwinkel J.. 2019. A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol. 27: 75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319154</ArticleId><ArticleId IdType="pubmed">30201512</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter, M. M., Martins T. A., Kulsvehagen L., Possnecker E., Duchemin W., Hogan S., Sanabria-Diaz G., Muller J., Chiappini A., Rychen J., et al. . 2022. Severe neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study. Nat. Commun. 13: 6777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9645766</ArticleId><ArticleId IdType="pubmed">36351919</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P., Rosen L. B., Zhang Q., Michailidis E., Hoffmann H. H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Beziat V., et al. . 2020. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370: eabd4585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Son, K., Jamil R., Chowdhury A., Mukherjee M., Venegas C., Miyasaki K., Zhang K., Patel Z., Salter B., Yuen A. C. Y., et al. . 2023. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur. Respir. J. 61: 2200970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Brussow, H., Brussow L.. 2021. Clinical evidence that the pandemic from 1889 to 1891 commonly called the Russian flu might have been an earlier coronavirus pandemic. Microb. Biotechnol. 14: 1860&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441924</ArticleId><ArticleId IdType="pubmed">34254725</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas, M., Rodriguez Y., Acosta-Ampudia Y., Monsalve D. M., Zhu C., Li Q. Z., Ramirez-Santana C., Anaya J. M.. 2022. Autoimmunity is a hallmark of post-COVID syndrome. J. Transl. Med. 20: 129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>An, H., Eun M., Yi J., Park J.. 2022. CRESSP: a comprehensive pipeline for prediction of immunopathogenic SARS-CoV-2 epitopes using structural properties of proteins. Brief. Bioinform. 23: bbac056.</Citation><ArticleIdList><ArticleId IdType="pubmed">35226074</ArticleId></ArticleIdList></Reference><Reference><Citation>James, J. A., Chen H., Young K. A., Bemis E. A., Seifert J., Bourn R. L., Deane K. D., Demoruelle M. K., Feser M., O&#x2019;Dell J. R., et al. . 2019. Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine 42: 76&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491794</ArticleId><ArticleId IdType="pubmed">30952617</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, R., Yen-Ting Chen T., Wang S. I., Hung Y. M., Chen H. Y., Wei C. J.. 2023. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine 56: 101783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830133</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G., Wang Q., Wang Y., Liu C., Wang L., Chen H., Jiao T., Hu C., Lei X., Guo L., et al. . 2021. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front. Immunol. 12: 791348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8720853</ArticleId><ArticleId IdType="pubmed">34987516</ArticleId></ArticleIdList></Reference><Reference><Citation>Manry, J., Bastard P., Gervais A., Voyer T. L., Rosain J., Philippot Q., Michailidis E., Hoffmann H. H., Eto S., Garcia-Prat M., et al. . 2022. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc. Natl. Acad. Sci. U. S. A. 119: e2200413119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9173764</ArticleId><ArticleId IdType="pubmed">35576468</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy, L., Orban Z. S., Koralnik I. J.. 2022. Case report: treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front. Med. (Lausanne) 9: 1003103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537824</ArticleId><ArticleId IdType="pubmed">36213654</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, B., Fan J., Huang J., Guo E., Fu Y., Liu S., Xiao R., Liu C., Lu F., Qin T., et al. . 2021. Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection. Nat. Commun. 12: 3501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8190301</ArticleId><ArticleId IdType="pubmed">34108465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaycox, J. R., Lucas C., Yildirim I., Dai Y., Wang E. Y., Monteiro V., Lord S., Carlin J., Kita M., Buckner J. H., et al. . 2023. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nat. Commun. 14: 1299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9996559</ArticleId><ArticleId IdType="pubmed">36894554</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>